logo-loader
viewIQ-AI Limited

IQ-AI files patent for non-toxic MRI scan technology

IQ-AI reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns

mri scanner
Recent research has highlighted the potential toxicity of gadolinium

IQ-AI Limited (LON:IQAI) has filed a patent for gadolinium-free magnetic resonance imaging (MRI) scan.

Over the past decade, research has shown the potential toxicity of gadolinium-based products and how they are retained in the body for several years.

The compounds have also been shown to potentially induce nephrogenic systemic fibrosis (NSF) in a small number of patients, particularly those with compromised kidney function.

IQ-AI, formerly known as Flying Brands, reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns.

The firm’s invention is based on deep learning (DL) techniques – a form of artificial intelligence – using only non-contrast MR images as inputs.

“We are delighted to announce the filing of this patent,” said chief executive of IQ-AI’s operating subsidiaries, David Smith.

“We believe the potential exists to develop, for the first time, a contrast agent-free imaging technology that should generate output comparable to traditional contrast-based imaging, offering significant savings to global healthcare systems.”

He added: “We now intend to develop the technology and conduct the clinical work necessary to prepare for worldwide regulatory submissions.”

Quick facts: IQ-AI Limited

Price: 5.12 GBX

LSE:IQAI
Market: LSE
Market Cap: £7.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FDA StoneChecker clearance a 'validation and tremendous leap...

IQ-AI Limited's (LON:IQAI) David Smith says the focus of their work on StoneChecker's moved into the commercial phase following FDA clearance for the product in the US. The software helps to identify the patients who would respond best to lithotripsy, which breaks up kidney stones using sound...

on 1/10/19

2 min read